Galleri® is a screening test; it is not for symptom evaluation or diagnosis but for additional screening in asymptomatic individuals. This article summarizes patient eligibility and the prescribing process.
Who Is Eligible?
- Asymptomatic adults aged 50 and over
- People with a family history of cancer
- Long-term smokers and those with occupational carcinogen exposure
- People with a previous cancer history under follow-up (with physician evaluation)
Who Is Not Eligible?
- Pregnant women
- Individuals aged 21 or under
- People undergoing active cancer treatment
- Those seeking inherited risk estimation (e.g. BRCA) — Galleri® is not used for this purpose
- Symptomatic patients with suspected cancer — they should be directed to diagnostic evaluation first
Prescribing and Sampling Process
- Patient eligibility: pre-assessment on age and risk factors; symptom screening.
- Prescription: the test is administered with a prescription; physician matching is provided for patients without one.
- Blood draw: 2 Streck cfDNA tubes; via the Omega Çare home nurse service in all 81 provinces or at the Omega Genetik Beytepe (Ankara) laboratory; no fasting required.
- Shipping: Ministry of Health-registered biological material transfer with cold-chain courier.
- Result: delivered to the physician within approximately 2 weeks; if a signal is found, the diagnostic work-up is planned with the CSO prediction and genetic counseling is provided where needed.
Post-Result Governance
A detected signal does not mean a definitive diagnosis; next steps (imaging, specialist consultation, tissue sampling if needed) are planned by the physician. Even when no signal is detected, national guideline screening programs (mammography, colonoscopy, low-dose CT etc.) continue as usual.
بوصفة طبية فقط — اختبار مسح. اختبار Galleri® ليس اختباراً تشخيصياً. النتيجة الإيجابية لا تعني تشخيص السرطان، والنتيجة السلبية لا تنفي وجوده. لا يُغني الاختبار عن فحوصات المسح الدورية التي يوصي بها طبيبك. لا يكتشف اختبار Galleri® جميع أنواع السرطان.